Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

CCNB1 (cyclin B1)

Written2009-01Carlos Perez-Stable
Geriatric Research, Education,, Clinical Center, Research Service, Veterans Affairs Medical Center, Miami, FL, USA 33125

(Note : for Links provided by Atlas : click)

Identity

Alias_namesCCNB
Other alias
HGNC (Hugo) CCNB1
LocusID (NCBI) 891
Atlas_Id 951
Location 5q13.2  [Link to chromosome band 5q13]
Location_base_pair Starts at 69167010 and ends at 69178243 bp from pter ( according to hg19-Feb_2009)  [Mapping CCNB1.png]
Fusion genes
(updated 2016)
APBB2 (4p14) / CCNB1 (5q13.2)CCNB1 (5q13.2) / CCDC84 (11q23.3)CCNB1 (5q13.2) / FNDC3A (13q14.2)
CCNB1 (5q13.2) / ULK4 (3p22.1)CDK7 (5q13.2) / CCNB1 (5q13.2)TP53 (17p13.1) / CCNB1 (5q13.2)

DNA/RNA

Description 9 exons; 2,087 bp; 433 residues CCNB1 transcript 1.
8 exons; 1,833 bp; 397 residues CCNB1 transcript 2.
Transcription Two alternative transcripts resulting from distinct transcription initiation sites. One is constitutively expressed and the other is G2/M cell cycle-regulated.
Pseudogene No verified pseudogenes.

Protein

Description Cyclin B1 (48.337 kDa) is a member of the cyclin family of proteins whose levels vary during the cell cycle in order to activate specific cyclin-dependent kinases (CDKs) required for the proper progression through the cell cycle. Cyclin B1 protein begins to increase during G2, peaks in mitosis, and is rapidly degraded before the cell cycle is completed. Cyclin B1 interacts with CDK1 to form a complex known as the maturation-promoting factor (MPF), which is essential for cell cycle progression through mitosis. When chromosomes are properly aligned during anaphase, rapid degradation of cyclin B1 by anaphase-promoting complex/cyclosome (APC/C) is required for mitotic exit and completion of the cell cycle.
Expression Cyclin B1 is overexpressed in a variety of cancers compared to normal cells and tissues. In normal tissues, low levels of cyclin B1 is detected in testis, thymus, bone marrow, and smooth muscle (CCNB1 expression). In most primary tumors, the expression of cyclin B1 is "unscheduled" (unrestricted to particular phases of the cycle), whereas in normal lymphocytes, the expression of cyclin B1 is restricted to very late S and G2 + M phases of the cell cycle (Gorczyca et al., 1997).
Localisation During interphase, cyclin B1 is concentrated in the cytoplasm but can shuttle to the nucleus (Pines and Hunter, 1991). At prophase, cyclin B1 accumulates in the nucleus and then to condensed chromatin, spindle microtubules, centrosomes, and chromatin during prometaphase (Bentley et al., 2007; Chen et al., 2008). This corresponds to localization of known CDK1 substrates, including nuclear lamins, microtubule and chromatin-associated proteins. Cyclin B1 is preferentially localized to unattached kinetochores and is involved in chromosome alignment in mitosis. In carcinomas, cytoplasmic expression of cyclin B1 is associated with a specific T-cell immune response (Egloff et al., 2006).
 
  Diagram of sequence domains for cyclin B1. The destruction box (DB) is required for degradation of cyclin B1 at the metaphase-to-anaphase transition. The cytoplasmic retention sequence (CRS) and the nuclear export signal (NES) are critical determinants of cyclin B1 localization during mitosis. The cyclin box is required for interaction with CDK1.
Function At entry into mitosis, cyclin B1-CDK1 promotes chromosome condensation, nuclear lamina resolution, and mitotic spindle assembly. Knockout mice without cyclin B1 or CDK1 are embryonic lethal, suggesting a requirement for cell proliferation (Brandeis et al., 1998). A long list of potential substrates for cyclin B1-CDK1 suggests other functions not yet known (CDK1 substrates).
Homology Cyclin B1 is a member of the highly conserved cyclin family and cyclin AB subfamily. The cyclin box is a region of protein sequence homology that is common to all members of the cyclin family and is required for interaction with CDK partner. There are at least three G1 cyclins (cyclin C, cyclin D, cyclin E) and two G2/M cyclins (cyclin A, cyclin B). Cyclin B2 also interacts with CDK1 but is not required for cell proliferation (Brandeis et al., 1998). Cyclin B3 binds to CDK2 and appears to function in meiosis (Nguyen et al., 2002).

Mutations

Note There are no known germinal or somatic mutations for cyclin B1 (CCNB1 COSMIC).

Implicated in

Note
  
Entity Prostate Carcinoma
Disease One study shows that the most powerful predictor of time to relapse of prostate cancer is a high ratio of cyclin A and B to the proliferation marker Ki67, i.e., the higher the ratio the longer time to relapse (Marshal et al., 1996). Another study, however, shows that high cyclin B1 expression in prostate cancer correlates with tumor grade and DNA ploidy but does not correlate with disease recurrence (Kallakury et al., 1999). Lower level of endogenous cyclin B1 increases the sensitivity of DNA mismatch repair-deficient prostate cancer cells to alkylating agents (Rasmussen et al., 2000). Overexpression of the oncogenic serine/threonine kinase PIM1 in prostate cancer cells increases cyclin B1 protein expression, which contributes to the development of polyploidy by delaying cytokinesis (Roh et al., 2005). The levels of cyclin B1 protein correlate with the ability of chemotherapy drugs to induce apoptosis of prostate cancer cells in vitro (Gomez et al., 2007).
  
  
Entity Breast Carcinoma
Disease Treatment of MCF7 breast cancer cells with cyclin B1-specific antisense oligonucleotide blocks Taxol-induced apoptosis, suggesting that cyclin B1-associated CDK1 activity plays an important role in the induction of apoptosis by Taxol (Shen et al., 1998). Memory T cells specific for cyclin B1 peptides were isolated from patients with breast cancer (Kao et al., 2001). Nuclear cyclin B1-positive breast carcinoma is resistant to adjuvant therapy, and nuclear cyclin B1 immunoreactivity is a potent prognostic factor in breast carcinoma patients (Suzuki et al., 2007). However, another study did not find a correlation with cyclin B1 overexpression and a worse outcome in breast cancer patients (Peters et al., 2004). Downregulation of cyclin B1 inhibits proliferation of breast cancer cell lines and sensitizes to Taxol (Yuan et al., 2004; Androic et al., 2008).
  
  
Entity Non-Small Cell Lung Carcinoma (NSCLC)
Disease Cyclin B1 is deregulated in NSCLC, particularly in the squamous cell carcinoma subtype (SCC), and a high level of cyclin B1 expression may be a prognostic marker for patients with early-stage SCC of the lung (Soria et al., 2000). Elevated levels of cyclin B1 expression may be an indicator of poor prognosis in NSCLC, particularly in non-SCC (Arinaga et al., 2003; Yoshida et al., 2004; Singhal et al., 2005). One study, however, did not find a prognostic relevance for cyclin B1 in NSCLC (Yoo et al., 2007).
  
  
Entity Small Cell Lung Carcinoma
Disease Cyclin B1 expression closely correlates with the Ki-67 labeling index in small cell lung carcinomas, suggesting that cyclin B1 is one of the key factors regulating cell proliferation in pulmonary neuroendocrine tumors. However, cyclin B1 did not correlate with patient survival (Igarashi et al., 2004).
  
  
Entity Esophageal Squamous Cell Carcinoma (ESCC)
Disease Cyclin B1 expression, especially nuclear, can be significant as a prognostic indicator in ESCC and may indicate a poor prognosis for patients (Murakami et al., 1999; Nozoe et al., 2002; Takeno et al., 2002). Isogenic ESCC cells overexpressing cyclin B1 reveal strong invasive growth and high potential of metastasis to lung in xenograft mice (Song et al., 2008).
  
  
Entity Head and Neck Squamous Carcinoma (HNSCC)
Disease HNSCC overexpressing cyclin B1 may be resistant to radiation therapy and cyclin B1 may be an indicator of the risk of recurrence and metastasis in patients having HNSCC receiving radiation therapy (Hassan et al., 2002).
  
  
Entity Renal Cell Carcinoma (RCC)
Disease Increased cyclin B1 in RCC and aberrant localization within the cytoplasm of tumor cells positively correlates with tumor progression, indicating the significant role of cyclin B1 in the development and pathogenesis of RCC. There may be prognostic value of cyclin B1 for RCC patients (Ikuerowo et al., 2006).
  
  
Entity Cervical Carcinoma
Disease The relationship between human papillomavirus virus (HPV) typing and cyclin B1 expression was not significant in cervical intraepithelial neoplasia and invasive cancer (Hashiguchi et al., 2004). HPV-16 E1 E4 protein sequesters CDK1/cyclin B1 onto the cytokeratin network, prevents the accumulation of active CDK1/cyclin B1 complexes in the nucleus, and hence prevents mitosis. This may create an environment optimal for viral DNA replication (Davy et al., 2005). HPV-18 decreases the fidelity of mitotic checkpoints and increases CDK1-associated kinase activity relative to control populations. The G2 checkpoint is aberrant by virtue of the stabilization of cyclin B1 mRNA through the upregulation of HuR protein (Cho et al., 2006). Up-regulation of cyclin B1 expression occurs in cervical cancer and an aberrant expression of cyclin B1 might play an important role in cervical carcinogenesis (Zhao et al., 2006). Reduction of cyclin B1 in HeLa cervical carcinoma cell lines inhibits proliferation, induces apoptosis, and sensitizes to Taxol (Yuan et al., 2006).
  
  
Entity Ovarian Carcinoma
Disease There is a significant correlation between percentages of polo-like kinase (PLK)-positive cells and histological grade of ovarian cancer. However, the expression of proliferating cell nuclear antigen, Ki-67, and cyclin B1 is independent of PLK expression (Takai et al., 2001).
  
  
Entity Pancreatic Cancer
Disease Overexpression of CDK1, cyclin A, and cyclin B1 occurs in 54.8, 54.9 and 56.4%, respectively, of the pancreatic adenocarcinomas. The findings suggest that CDK1 and cyclin A play a role in the progression of pancreatic adenocarcinoma, while the clinical significance of cyclin B1 remains to be clarified because of its more random expression (Ito et al., 2002).
  
  
Entity Liver Cancer
Disease Fifteen of 100 patients with hepatocellular carcinoma (HCC) have autoantibodies reactive with cyclin B1 (Covini et al., 1997). CDK1 overexpression is directly related to advanced stage, portal invasion, intrahepatic metastasis, poor differentiation, high alpha-fetoprotein level, large size, high Ki-67 labeling index, and poor prognosis. Cyclin A and B1 overexpression shows a similar tendency to that of CDK1, but they are not recognized as independent prognostic factors (Ito et al., 2000). Hepatitis C virus (HCV) proteins increase the activity of the cyclin B1-CDK1 complex via the p38 MAPK and JNK pathways and promotes nuclear import of cyclin B1 (Spaziani et al., 2006). TIS21 negatively regulates hepatocarcinogenesis in part by disruption of the FoxM1-cyclin B1 regulatory loop, thereby inhibiting proliferation of transformed cells developed in mouse and human livers (Park et al., 2008).
  
  
Entity Gastric Cancer
Disease Cyclin B1 overexpression does not correlate with survival of patients with gastric cancer (Brien et al., 1998). Another study shows that cyclin B1 protein overexpression is closely associated with less aggressive gastric cancers (Yasuda et al., 2002). A third study shows that overexpression of cyclin B1 may play an important role in lymph node metastatic potential of gastric cancer (Kim, 2007).
  
  
Entity Colorectal Adenocarcinoma
Disease The majority of colorectal cancers express high levels of cyclin B1, consistent with a high rate of cell proliferation (Wang et al., 1997). Cyclin B1 expression does not change in recurrent colorectal adenocarcinoma compared to primary tumors (Seong et al., 1999). A study suggests a close correlation between a lack of cyclin B1 immunostaining and a stronger metastatic behavior in colorectal cancer (Korenaga et al., 2002). Cyclin B1, but not cyclin G1, may promote colorectal carcinogenesis and later metastasis to lymph nodes (Li et al., 2003). High expression of cyclin B1 is a frequent and early event in colorectal carcinomas. However, cyclin B1 expression is neither a predictor of prognosis or survival in patients with colorectal cancer nor a suitable tool for identifying subgroups of patients at higher risk for disease recurrence (Grabsch et al., 2004; Bondi et al., 2005). Adenomatous polyposis coli (APC) is a substrate for recombinant human CDK1-cyclin B1, implicating phosphorylation as a mechanism for regulating APC function via a link to the cell cycle (Trzepacz et al., 1997).
  
  
Entity Thyroid Carcinoma
Disease Cyclin B1 is overexpressed in four undifferentiated thyroid carcinomas (19.0%), but not in thyroid carcinomas of other types. CDK1 overexpression is also related to carcinoma differentiation (p < 0.0001), and is directly linked to cyclin A overexpression (p < 0.0001), but not to cyclin B1 overexpression (Ito et al., 2002). Cyclin B1 expression does not have any prognostic significance for poorly differentiated follicular thyroid carcinoma (Pulcrano et al., 2007).
  
  
Entity Tongue Carcinoma
Disease Cyclin B1 is overexpressed in a subset of squamous cell carcinoma of the tongue and is associated with a more aggressive biological behavior of the disease (Hassan et al., 2001).
  
  
Entity Skin Melanoma
Disease The expression of cyclin B1 (P < 0.0001) is significantly higher in melanomas in comparison with Spitz nevi (Stefanaki et al., 2007).
  
  
Entity Glioma
Disease Cyclin B1 is a gene identified to be increased in glioma cells invading brain slice cultures (Holtkamp et al., 2005). Human glioma tissue microarrays indicate a positive expression rate of CDK1/cyclin B1 with a positive correlation with pathologic grades (Chen et al., 2008).
  
  
Entity Astrocytoma
Disease Nuclear and cytoplasmic cyclin B1 immunostaining correlates well with the tumor grade but shows poor correlation with Ki-67 in astrocytomas (Allan et al., 2000). There is a significant increase in cyclin B1 (P = 0.002) expression with increasing grade from diffuse astrocytoma through anaplastic astrocytoma to glioblastoma, suggesting a potential as a marker of tumor grade (Scott et al., 2005).
  
  
Entity Medulloblastoma
Disease Cyclin B1 expression shows no statistical significant effect on survival in medulloblastoma (Neben et al., 2004). Another study shows that the combined expression of MYC and the lactate dehydrogenase B (LDHB)/cyclin B1 gene signature is able to predict survival in medulloblastoma patients and are strong prognostic markers independent of the clinical parameters, metastasis, and residual disease (de Haas et al., 2008).
  
  
Entity Osteosarcoma
Disease E2F-1 overexpression in the U2OS osteosarcoma cell line increases cyclin B1, CDK1 activity, sensitivity to paclitaxel, and the cellular growth rate. Knockdown of cyclin B1 using an RNA interference decreases cellular growth rate and an increases resistance to paclitaxel (Russo et al., 2006).
  
  
Entity Leukemia and Lymphoma
Disease Derangement of cyclin B1 and CDK1 kinetics and functions is more profound in Hodgkin's disease than in anaplastic large cell lymphomas (Leoncini et al., 1998). Cyclin B1 and CDK1 appears to be involved in the genesis or progression of malignant lymphoma but only CDK1 is a useful marker for response to chemotherapy (Jin and Park, 2002). Overexpression of cyclin B1 in follicular lymphomas correlates with better response to chemotherapy (Bjorck et al., 2005). Nuclear and/or cytoplasmic staining in > or = 1% of diffuse large B-cell lymphoma cells is significantly associated with shorter overall survival (Obermann et al., 2005). Cyclin B1 protein accumulates in the nucleus of cells that are sensitive to gamma radiation-induced apoptosis (thymocytes, lymphoid cell lines), but remains cytoplasmic in apoptosis-resistant cells (primary and transformed fibroblasts) (Porter et al., 2003).
  
  
Entity Alzheimer's Disease (AD)
Disease Cyclin B1 and CDK1 are enriched in neurons with neurofibrillary tangles (NFT), characteristic of AD. This suggests that aberrantly reexpressed cyclin B1/CDK1 in NFT-bearing neurons in AD brain contributes to the generation of M-phase phospho-epitopes in NFT (Vincent et al., 1997). Cyclin B1 is not detected in control subjects but is expressed in subiculum, dentate gyrus, and CA1 region of patients with AD pathology (Nagy et al., 1997). Aberrant expression of cyclin B1 is identified in the hippocampus, subiculum, locus coeruleus, and dorsal raphe nuclei, but not inferotemporal cortex or cerebellum of AD cases. Control subjects show no significant expression of cyclin B1 in any of the six regions. Disregulation of various components of the cell cycle may be a significant contributor to regionally specific neuronal death in AD (Busser et al., 1998). Direct interactions between cyclin B1 and Abeta may provide potential mechanisms for the cytotoxicity of the Abeta peptide (Milton, 2002). CIP-1-associated regulator of cyclin B (CARB), a protein that associates with cyclin B1, increases in intraneuronal NFT neurofibrillary tangles in susceptible hippocampal and cortical neurons in AD. By marked contrast, CARB is found only at background levels in these neuronal populations in nondiseased age-matched controls (Zhu et al., 2004). Cdh1/Hct1, an activator of the E3-ubiquitin ligase anaphase-promoting complex (APC) that promotes the ubiquitylation and degradation of mitotic cyclins, is required to prevent the accumulation of cyclin B1 in terminally differentiated neurons. By keeping cyclin B1 low, Cdh1 prevents these neurons from entering an aberrant S phase that leads to apoptotic cell death. These results provide an explanation for the mechanism of cyclin B1 reactivation that occurs in the brain of patients suffering from AD (Almeida et al., 2005).
  
  
Entity Neurodegenerative Disease
Disease Neurons containing characteristic neurodegenerative lesions in a subset of diseases including Down Syndrome, Frontotemporal Dementia linked to chromosome 17, Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinson-Amyotrophic Lateral Sclerosis of Guam, Niemann Pick disease type C, and Pick's disease also display mitotic indices including cyclin B1 expression (Husseman et al., 2000).
Cytogenetics Chromosome instability resulting from Tax-induced deficiency of cyclin B1 and securin may be the explanation for the highly aneuploid nature of adult T-cell leukemia cells (Liu et al., 2003).
  

Bibliography

Overexpression of cyclin A and cyclin B1 proteins in astrocytomas.
Allan K, Jordan RC, Ang LC, Taylor M, Young B.
Arch Pathol Lab Med. 2000 Feb;124(2):216-20.
PMID 10656729
 
Cdh1/Hct1-APC is essential for the survival of postmitotic neurons.
Almeida A, Bolanos JP, Moreno S.
J Neurosci. 2005 Sep 7;25(36):8115-21.
PMID 16148219
 
Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol.
Androic I, Kramer A, Yan R, Rodel F, Gatje R, Kaufmann M, Strebhardt K, Yuan J.
BMC Cancer. 2008 Dec 29;8(1):391. [Epub ahead of print]
PMID 19113992
 
Clinical implication of cyclin B1 in non-small cell lung cancer.
Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Kimura Y, Uchida Y.
Oncol Rep. 2003 Sep-Oct;10(5):1381-6.
PMID 12883711
 
Distinct sequence elements of cyclin B1 promote localization to chromatin, centrosomes, and kinetochores during mitosis.
Bentley AM, Normand G, Hoyt J, King RW.
Mol Biol Cell. 2007 Dec;18(12):4847-58. Epub 2007 Sep 19.
PMID 17881737
 
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma.
Bjorck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Bjorkholm M, Borrebaeck CA, Porwit-MacDonald A, Nordenskjold M.
Blood. 2005 Apr 1;105(7):2908-15. Epub 2004 Dec 2.
PMID 15576476
 
Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome.
Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IR.
J Clin Pathol. 2005 May;58(5):509-14.
PMID 15858123
 
Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero.
Brandeis M, Rosewell I, Carrington M, Crompton T, Jacobs MA, Kirk J, Gannon J, Hunt T.
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4344-9.
PMID 9539739
 
Prognostic factors in gastric cancer.
Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ.
Mod Pathol. 1998 Sep;11(9):870-7.
PMID 9758367
 
Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain.
Busser J, Geldmacher DS, Herrup K.
J Neurosci. 1998 Apr 15;18(8):2801-7.
PMID 9525997
 
Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo.
Chen H, Huang Q, Dong J, Zhai DZ, Wang AD, Lan Q.
BMC Cancer. 2008 Jan 29;8:29.
PMID 18230152
 
Cyclin B1 is localized to unattached kinetochores and contributes to efficient microtubule attachment and proper chromosome alignment during mitosis.
Chen Q, Zhang X, Jiang Q, Clarke PR, Zhang C.
Cell Res. 2008 Feb;18(2):268-80.
PMID 18195732
 
Elevation of cyclin B1, active cdc2, and HuR in cervical neoplasia with human papillomavirus type 18 infection.
Cho NH, Kang S, Hong S, An HJ, Choi YH, Jeong GB, Choi HK.
Cancer Lett. 2006 Feb 8;232(2):170-8.
PMID 16458113
 
Immune response to cyclin B1 in hepatocellular carcinoma.
Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM.
Hepatology. 1997 Jan;25(1):75-80.
PMID 8985268
 
Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes.
Davy CE, Jackson DJ, Raj K, Peh WL, Southern SA, Das P, Sorathia R, Laskey P, Middleton K, Nakahara T, Wang Q, Masterson PJ, Lambert PF, Cuthill S, Millar JB, Doorbar J.
J Virol. 2005 Apr;79(7):3998-4011.
PMID 15767402
 
Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer.
Egloff AM, Vella LA, Finn OJ.
Cancer Res. 2006 Jan 1;66(1):6-9. Review
PMID 16397206
 
Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.
Gomez LA, de Las Pozas A, Reiner T, Burnstein K, Perez-Stable C.
Mol Cancer Ther. 2007 May;6(5):1534-43.
PMID 17513602
 
Laser scanning cytometric analysis of cyclin B1 in primary human malignancies.
Gorczyca W, Sarode V, Juan G, Melamed MR, Darzynkiewicz Z.
Mod Pathol. 1997 May;10(5):457-62.
PMID 9160310
 
Prognostic value of cyclin B1 protein expression in colorectal cancer.
Grabsch H, Lickvers K, Hansen O, Takeno S, Willers R, Stock W, Gabbert HE, Mueller W.
Am J Clin Pathol. 2004 Oct;122(4):511-6.
PMID 15487447
 
Relationship between HPV typing and the status of G2 cell cycle regulators in cervical neoplasia.
Hashiguchi Y, Tsuda H, Nishimura S, Inoue T, Kawamura N, Yamamoto K.
Oncol Rep. 2004 Sep;12(3):587-91.
PMID 15289842
 
Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma.
Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D, Hong WK, Mao L.
Cancer Res. 2002 Nov 15;62(22):6414-7.
PMID 12438226
 
Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue.
Hassan KA, El-Naggar AK, Soria JC, Liu D, Hong WK, Mao L.
Clin Cancer Res. 2001 Aug;7(8):2458-62.
PMID 11489826
 
Brain slice invasion model reveals genes differentially regulated in glioma invasion.
Holtkamp N, Afanasieva A, Elstner A, van Landeghem FK, Konneker M, Kuhn SA, Kettenmann H, von Deimling A.
Biochem Biophys Res Commun. 2005 Nov 4;336(4):1227-33.
PMID 16171788
 
Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases.
Husseman JW, Nochlin D, Vincent I.
Neurobiol Aging. 2000 Nov-Dec;21(6):815-28.
PMID 11124425
 
Divergent cyclin B1 expression and Rb/p16/cyclin D1 pathway aberrations among pulmonary neuroendocrine tumors.
Igarashi T, Jiang SX, Kameya T, Asamura H, Sato Y, Nagai K, Okayasu I.
Mod Pathol. 2004 Oct;17(10):1259-67.
PMID 15154011
 
Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients.
Ikuerowo SO, Kuczyk MA, Mengel M, van der Heyde E, Shittu OB, Vaske B, Jonas U, Machtens S, Serth J.
Int J Cancer. 2006 Aug 15;119(4):867-74.
PMID 16557593
 
Expression of the G2-M modulators in pancreatic adenocarcinoma.
Ito Y, Takeda T, Wakasa K, Tsujimoto M, Okada M, Matsuura N.
Pancreatology. 2002;2(2):138-45.
PMID 12123094
 
Expression of G2-M modulators in thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with differentiation.
Ito Y, Yoshida H, Nakano K, Takamura Y, Kobayashi K, Yokozawa T, Matsuzuka F, Matsuura N, Kuma K, Miyauchi A.
Pathol Res Pract. 2002;198(6):397-402.
PMID 12166896
 
Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications.
Jin YH, Park CK.
J Korean Med Sci. 2002 Jun;17(3):322-7.
PMID 12068134
 
The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Kallakury BV, Sheehan CE, Rhee SJ, Fisher HA, Kaufman RP Jr, Rifkin MD, Ross JS.
Cancer. 1999 Apr 1;85(7):1569-76.
PMID 10193948
 
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells.
Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ.
J Exp Med. 2001 Nov 5;194(9):1313-23.
PMID 11696596
 
Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.
Kim DH.
Yonsei Med J. 2007 Aug 31;48(4):694-700.
PMID 17722244
 
The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer.
Korenaga D, Takesue F, Yasuda M, Honda M, Nozoe T, Inutsuka S.
Surgery. 2002 Jan;131(1 Suppl):S114-20.
PMID 11821797
 
Cellular kinetic differences between Hodgkin's and anaplastic large cell lymphomas: relation to the expression of p34cdc2 and cyclin B-1.
Leoncini L, Megha T, Lazzi S, Bellan C, Luzi P, Tosi P, Cevenini G, Barbini P, Ascani S, Briskomatis A, Pileri S, Kraft R, Laissue JA, Cottier H.
Int J Cancer. 1998 Jul 29;77(3):408-14.
PMID 9663604
 
Cyclin B1, unlike cyclin G1, increases significantly during colorectal carcinogenesis and during later metastasis to lymph nodes.
Li JQ, Kubo A, Wu F, Usuki H, Fujita J, Bandoh S, Masaki T, Saoo K, Takeuchi H, Kobayashi S, Imaida K, Maeta H, Ishida T, Kuriyama S.
Int J Oncol. 2003 May;22(5):1101-10.
PMID 12684677
 
Human T-lymphotropic virus type 1 oncoprotein tax promotes unscheduled degradation of Pds1p/securin and Clb2p/cyclin B1 and causes chromosomal instability.
Liu B, Liang MH, Kuo YL, Liao W, Boros I, Kleinberger T, Blancato J, Giam CZ.
Mol Cell Biol. 2003 Aug;23(15):5269-81.
PMID 12861013
 
Expression of cell cycle-regulated proteins in prostate cancer.
Mashal RD, Lester S, Corless C, Richie JP, Chandra R, Propert KJ, Dutta A.
Cancer Res. 1996 Sep 15;56(18):4159-63.
PMID 8797586
 
The amyloid-beta peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity.
Milton NG.
Neurosci Lett. 2002 Apr 5;322(2):131-3.
PMID 11958860
 
Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma.
Murakami H, Furihata M, Ohtsuki Y, Ogoshi S.
Virchows Arch. 1999 Feb;434(2):153-8.
PMID 10071250
 
Cell cycle markers in the hippocampus in Alzheimer's disease.
Nagy Z, Esiri MM, Cato AM, Smith AD.
Acta Neuropathol. 1997 Jul;94(1):6-15.
PMID 9224524
 
Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival.
Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P.
Cancer Res. 2004 May 1;64(9):3103-11.
PMID 15126347
 
Characterization and expression of mammalian cyclin b3, a prepachytene meiotic cyclin.
Nguyen TB, Manova K, Capodieci P, Lindon C, Bottega S, Wang XY, Refik-Rogers J, Pines J, Wolgemuth DJ, Koff A.
J Biol Chem. 2002 Nov 1;277(44):41960-9. Epub 2002 Aug 15.
PMID 12185076
 
Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus.
Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K.
Clin Cancer Res. 2002 Mar;8(3):817-22.
PMID 11895914
 
Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Obermann EC, Went P, Pehrs AC, Tzankov A, Wild PJ, Pileri S, Hofstaedter F, Dirnhofer S.
Oncol Rep. 2005 Dec;14(6):1461-7.
PMID 16273239
 
TIS21 negatively regulates hepatocarcinogenesis by disruption of cyclin B1-Forkhead box M1 regulation loop.
Park TJ, Kim JY, Oh SP, Kang SY, Kim BW, Wang HJ, Song KY, Kim HC, Lim IK.
Hepatology. 2008 May;47(5):1533-43.
PMID 18393292
 
Prognostic value of cell cycle regulator molecules in surgically resected stage I and II breast cancer.
Peters MG, Vidal Mdel C, Gimenez L, Mauro L, Armanasco E, Cresta C, Bal de Kier Joffe E, Puricelli L.
Oncol Rep. 2004 Nov;12(5):1143-50.
PMID 15492807
 
Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport.
Pines J, Hunter T.
J Cell Biol. 1991 Oct;115(1):1-17.
PMID 1717476
 
Nuclear localization of cyclin B1 regulates DNA damage-induced apoptosis.
Porter LA, Cukier IH, Lee JM.
Blood. 2003 Mar 1;101(5):1928-33. Epub 2002 Nov 7.
PMID 12424202
 
Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification.
Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F, Schlumberger M.
Thyroid. 2007 Jul;17(7):639-46.
PMID 17696834
 
The human cyclin B1 protein modulates sensitivity of DNA mismatch repair deficient prostate cancer cell lines to alkylating agents.
Rasmussen LJ, Rasmussen M, Lutzen A, Bisgaard HC, Singh KK.
Exp Cell Res. 2000 May 25;257(1):127-34.
PMID 10854060
 
Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1.
Roh M, Song C, Kim J, Abdulkadir SA.
J Biol Chem. 2005 Dec 9;280(49):40568-77. Epub 2005 Oct 12.
PMID 16221667
 
E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents.
Russo AJ, Magro PG, Hu Z, Li WW, Peters R, Mandola J, Banerjee D, Bertino JR.
Cancer Res. 2006 Jul 15;66(14):7253-60.
PMID 16849574
 
Cdk1 is sufficient to drive the mammalian cell cycle.
Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, Caceres JF, Dubus P, Malumbres M, Barbacid M.
Nature. 2007 Aug 16;448(7155):811-5.
PMID 17700700
 
Immunohistochemical estimation of cell cycle entry and phase distribution in astrocytomas: applications in diagnostic neuropathology.
Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Burnet NG, Coleman N.
Neuropathol Appl Neurobiol. 2005 Oct;31(5):455-66.
PMID 16150117
 
Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas.
Seong J, Chung EJ, Kim H, Kim GE, Kim NK, Sohn SK, Min JS, Suh CO.
Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1167-73.
PMID 10613309
 
Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells.
Shen SC, Huang TS, Jee SH, Kuo ML.
Cell Growth Differ. 1998 Jan;9(1):23-9.
PMID 9438385
 
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM.
Clin Cancer Res. 2005 Jun 1;11(11):3974-86. Review
PMID 15930332
 
Overexpression of cyclin B1 in human esophageal squamous cell carcinoma cells induces tumor cell invasive growth and metastasis.
Song Y, Zhao C, Dong L, Fu M, Xue L, Huang Z, Tong T, Zhou Z, Chen A, Yang Z, Lu N, Zhan Q.
Carcinogenesis. 2008 Feb;29(2):307-15. Epub 2007 Nov 28.
PMID 18048386
 
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication.
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L.
Cancer Res. 2000 Aug 1;60(15):4000-4.
PMID 10945597
 
Role of p38 MAPK and RNA-dependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1.
Spaziani A, Alisi A, Sanna D, Balsano C.
J Biol Chem. 2006 Apr 21;281(16):10983-9. Epub 2006 Jan 30.
PMID 16446363
 
Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
Stefanaki C, Stefanaki K, Antoniou C, Argyrakos T, Patereli A, Stratigos A, Katsambas A.
J Am Acad Dermatol. 2007 May;56(5):815-24.
PMID 17437889
 
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor.
Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Horie K, Inoue S, Sasano H.
Cancer Sci. 2007 May;98(5):644-51. Epub 2007 Mar 14.
PMID 17359284
 
Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage.
Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I.
Cancer Lett. 2001 Mar 10;164(1):41-9.
PMID 11166914
 
Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma.
Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W.
Cancer. 2002 Jun 1;94(11):2874-81.
PMID 12115375
 
Phosphorylation of the tumor suppressor adenomatous polyposis coli (APC) by the cyclin-dependent kinase p34.
Trzepacz C, Lowy AM, Kordich JJ, Groden J.
J Biol Chem. 1997 Aug 29;272(35):21681-4.
PMID 9268294
 
Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain.
Vincent I, Jicha G, Rosado M, Dickson DW.
J Neurosci. 1997 May 15;17(10):3588-98.
PMID 9133382
 
Overexpression of cyclin B1 in human colorectal cancers.
Wang A, Yoshimi N, Ino N, Tanaka T, Mori H.
J Cancer Res Clin Oncol. 1997;123(2):124-7.
PMID 9030252
 
Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study.
Yasuda M, Takesue F, Inutsuka S, Honda M, Nozoe T, Korenaga D.
J Cancer Res Clin Oncol. 2002 Aug;128(8):412-6. Epub 2002 Jul 26.
PMID 12200597
 
Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis.
Yoo J, Jung JH, Lee MA, Seo KJ, Shim BY, Kim SH, Cho DG, Ahn MI, Kim CH, Cho KD, Kang SJ, Kim HK.
J Korean Med Sci. 2007 Apr;22(2):318-25.
PMID 17449943
 
The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer.
Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H.
Ann Oncol. 2004 Feb;15(2):252-6.
PMID 14760118
 
Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo.
Yuan J, Kramer A, Matthess Y, Yan R, Spankuch B, Gatje R, Knecht R, Kaufmann M, Strebhardt K.
Oncogene. 2006 Mar 16;25(12):1753-62.
PMID 16278675
 
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells.
Yuan J, Yan R, Kramer A, Eckerdt F, Roller M, Kaufmann M, Strebhardt K.
Oncogene. 2004 Jul 29;23(34):5843-52.
PMID 15208674
 
Expression profiling of cyclin B1 and D1 in cervical carcinoma.
Zhao M, Kim YT, Yoon BS, Kim SW, Kang MH, Kim SH, Kim JH, Kim JW, Park YW.
Exp Oncol. 2006 Mar;28(1):44-8.
PMID 16614707
 
Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease.
Zhu X, McShea A, Harris PL, Raina AK, Castellani RJ, Funk JO, Shah S, Atwood C, Bowen R, Bowser R, Morelli L, Perry G, Smith MA.
J Neurosci Res. 2004 Mar 1;75(5):698-703.
PMID 14991845
 
Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.
de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, Baas F, Versteeg R, Kool M.
Clin Cancer Res. 2008 Jul 1;14(13):4154-60.
PMID 18593994
 

Citation

This paper should be referenced as such :
Perez-Stable, C
CCNB1 (cyclin B1)
Atlas Genet Cytogenet Oncol Haematol. 2009;13(12):911-917.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/CCNB1ID951ch5q13.html


External links

Nomenclature
HGNC (Hugo)CCNB1   1579
Cards
AtlasCCNB1ID951ch5q13
Entrez_Gene (NCBI)CCNB1  891  cyclin B1
AliasesCCNB
GeneCards (Weizmann)CCNB1
Ensembl hg19 (Hinxton)ENSG00000134057 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000134057 [Gene_View]  chr5:69167010-69178243 [Contig_View]  CCNB1 [Vega]
ICGC DataPortalENSG00000134057
TCGA cBioPortalCCNB1
AceView (NCBI)CCNB1
Genatlas (Paris)CCNB1
WikiGenes891
SOURCE (Princeton)CCNB1
Genetics Home Reference (NIH)CCNB1
Genomic and cartography
GoldenPath hg38 (UCSC)CCNB1  -     chr5:69167010-69178243 +  5q13.2   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)CCNB1  -     5q13.2   [Description]    (hg19-Feb_2009)
EnsemblCCNB1 - 5q13.2 [CytoView hg19]  CCNB1 - 5q13.2 [CytoView hg38]
Mapping of homologs : NCBICCNB1 [Mapview hg19]  CCNB1 [Mapview hg38]
OMIM123836   
Gene and transcription
Genbank (Entrez)AI972071 AK289431 AM851053 AY027761 AY027762
RefSeq transcript (Entrez)NM_031966
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)CCNB1
Cluster EST : UnigeneHs.23960 [ NCBI ]
CGAP (NCI)Hs.23960
Alternative Splicing GalleryENSG00000134057
Gene ExpressionCCNB1 [ NCBI-GEO ]   CCNB1 [ EBI - ARRAY_EXPRESS ]   CCNB1 [ SEEK ]   CCNB1 [ MEM ]
Gene Expression Viewer (FireBrowse)CCNB1 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)891
GTEX Portal (Tissue expression)CCNB1
Protein : pattern, domain, 3D structure
UniProt/SwissProtP14635   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP14635  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP14635
Splice isoforms : SwissVarP14635
PhosPhoSitePlusP14635
Domaine pattern : Prosite (Expaxy)CYCLINS (PS00292)   
Domains : Interpro (EBI)Cyclin-like    Cyclin_C-dom    Cyclin_N   
Domain families : Pfam (Sanger)Cyclin_C (PF02984)    Cyclin_N (PF00134)   
Domain families : Pfam (NCBI)pfam02984    pfam00134   
Domain families : Smart (EMBL)CYCLIN (SM00385)  Cyclin_C (SM01332)  
Conserved Domain (NCBI)CCNB1
DMDM Disease mutations891
Blocks (Seattle)CCNB1
PDB (SRS)2B9R    2JGZ    4Y72    4YC3    5HQ0    5LQF   
PDB (PDBSum)2B9R    2JGZ    4Y72    4YC3    5HQ0    5LQF   
PDB (IMB)2B9R    2JGZ    4Y72    4YC3    5HQ0    5LQF   
PDB (RSDB)2B9R    2JGZ    4Y72    4YC3    5HQ0    5LQF   
Structural Biology KnowledgeBase2B9R    2JGZ    4Y72    4YC3    5HQ0    5LQF   
SCOP (Structural Classification of Proteins)2B9R    2JGZ    4Y72    4YC3    5HQ0    5LQF   
CATH (Classification of proteins structures)2B9R    2JGZ    4Y72    4YC3    5HQ0    5LQF   
SuperfamilyP14635
Human Protein AtlasENSG00000134057
Peptide AtlasP14635
HPRD00454
IPIIPI00745793   IPI00294696   IPI00966971   IPI00966645   IPI00966293   IPI00966094   
Protein Interaction databases
DIP (DOE-UCLA)P14635
IntAct (EBI)P14635
FunCoupENSG00000134057
BioGRIDCCNB1
STRING (EMBL)CCNB1
ZODIACCCNB1
Ontologies - Pathways
QuickGOP14635
Ontology : AmiGOG2/M transition of mitotic cell cycle  spindle pole  condensed nuclear chromosome outer kinetochore  oocyte maturation  in utero embryonic development  negative regulation of protein phosphorylation  cyclin-dependent protein serine/threonine kinase activity  patched binding  protein binding  nucleus  nucleoplasm  cytoplasm  mitochondrial matrix  centrosome  cytosol  cytosol  protein complex assembly  DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest  mitotic spindle organization  mitotic nuclear envelope disassembly  mitotic metaphase plate congression  spermatogenesis  response to mechanical stimulus  negative regulation of gene expression  membrane  protein kinase binding  anaphase-promoting complex-dependent catabolic process  positive regulation of mRNA 3'-end processing  positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G2/M transition of mitotic cell cycle  positive regulation of histone phosphorylation  histone kinase activity  tissue regeneration  response to drug  protein ubiquitination involved in ubiquitin-dependent protein catabolic process  positive regulation of mitotic cell cycle  response to DDT  positive regulation of fibroblast proliferation  digestive tract development  cell division  negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle  positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition  regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle  regulation of cell cycle  positive regulation of attachment of spindle microtubules to kinetochore  ventricular cardiac muscle cell development  positive regulation of cardiac muscle cell proliferation  regulation of chromosome condensation  cyclin-dependent protein serine/threonine kinase activator activity  cellular response to iron(III) ion  cellular response to fatty acid  cellular response to organic cyclic compound  cellular response to hypoxia  regulation of mitotic cell cycle spindle assembly checkpoint  cyclin B1-CDK1 complex  positive regulation of mitochondrial ATP synthesis coupled electron transport  histone H3-S10 phosphorylation involved in chromosome condensation  
Ontology : EGO-EBIG2/M transition of mitotic cell cycle  spindle pole  condensed nuclear chromosome outer kinetochore  oocyte maturation  in utero embryonic development  negative regulation of protein phosphorylation  cyclin-dependent protein serine/threonine kinase activity  patched binding  protein binding  nucleus  nucleoplasm  cytoplasm  mitochondrial matrix  centrosome  cytosol  cytosol  protein complex assembly  DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest  mitotic spindle organization  mitotic nuclear envelope disassembly  mitotic metaphase plate congression  spermatogenesis  response to mechanical stimulus  negative regulation of gene expression  membrane  protein kinase binding  anaphase-promoting complex-dependent catabolic process  positive regulation of mRNA 3'-end processing  positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G2/M transition of mitotic cell cycle  positive regulation of histone phosphorylation  histone kinase activity  tissue regeneration  response to drug  protein ubiquitination involved in ubiquitin-dependent protein catabolic process  positive regulation of mitotic cell cycle  response to DDT  positive regulation of fibroblast proliferation  digestive tract development  cell division  negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle  positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition  regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle  regulation of cell cycle  positive regulation of attachment of spindle microtubules to kinetochore  ventricular cardiac muscle cell development  positive regulation of cardiac muscle cell proliferation  regulation of chromosome condensation  cyclin-dependent protein serine/threonine kinase activator activity  cellular response to iron(III) ion  cellular response to fatty acid  cellular response to organic cyclic compound  cellular response to hypoxia  regulation of mitotic cell cycle spindle assembly checkpoint  cyclin B1-CDK1 complex  positive regulation of mitochondrial ATP synthesis coupled electron transport  histone H3-S10 phosphorylation involved in chromosome condensation  
Pathways : BIOCARTA [Genes]   
Pathways : KEGGFoxO signaling pathway    Cell cycle    Oocyte meiosis    p53 signaling pathway    Progesterone-mediated oocyte maturation   
REACTOMEP14635 [protein]
REACTOME PathwaysR-HSA-8852276 [pathway]   
NDEx NetworkCCNB1
Atlas of Cancer Signalling NetworkCCNB1
Wikipedia pathwaysCCNB1
Orthology - Evolution
OrthoDB891
GeneTree (enSembl)ENSG00000134057
Phylogenetic Trees/Animal Genes : TreeFamCCNB1
HOVERGENP14635
HOGENOMP14635
Homologs : HomoloGeneCCNB1
Homology/Alignments : Family Browser (UCSC)CCNB1
Gene fusions - Rearrangements
Fusion : MitelmanCDK7/CCNB1 [5q13.2/5q13.2]  [t(5;5)(q13;q13)]  
Fusion: TCGACDK7 5q13.2 CCNB1 5q13.2 BRCA
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerCCNB1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)CCNB1
dbVarCCNB1
ClinVarCCNB1
1000_GenomesCCNB1 
Exome Variant ServerCCNB1
ExAC (Exome Aggregation Consortium)CCNB1 (select the gene name)
Genetic variants : HAPMAP891
Genomic Variants (DGV)CCNB1 [DGVbeta]
DECIPHERCCNB1 [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisCCNB1 
Mutations
ICGC Data PortalCCNB1 
TCGA Data PortalCCNB1 
Broad Tumor PortalCCNB1
OASIS PortalCCNB1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICCCNB1  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDCCNB1
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch CCNB1
DgiDB (Drug Gene Interaction Database)CCNB1
DoCM (Curated mutations)CCNB1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)CCNB1 (select a term)
intoGenCCNB1
NCG5 (London)CCNB1
Cancer3DCCNB1(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM123836   
Orphanet
MedgenCCNB1
Genetic Testing Registry CCNB1
NextProtP14635 [Medical]
TSGene891
GENETestsCCNB1
Target ValidationCCNB1
Huge Navigator CCNB1 [HugePedia]
snp3D : Map Gene to Disease891
BioCentury BCIQCCNB1
ClinGenCCNB1
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD891
Chemical/Pharm GKB GenePA95
Clinical trialCCNB1
Miscellaneous
canSAR (ICR)CCNB1 (select the gene name)
Probes
Litterature
PubMed398 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineCCNB1
EVEXCCNB1
GoPubMedCCNB1
iHOPCCNB1
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 30 11:02:44 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.